Kenvue Inc. (NYSE:KVUE) Holdings Cut by Knuff & Co LLC

Knuff & Co LLC decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 64.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,484 shares of the company’s stock after selling 17,263 shares during the quarter. Knuff & Co LLC’s holdings in Kenvue were worth $204,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Clearstead Advisors LLC acquired a new position in shares of Kenvue during the 3rd quarter worth $25,000. Planned Solutions Inc. acquired a new position in shares of Kenvue during the 4th quarter worth $27,000. EverSource Wealth Advisors LLC acquired a new position in shares of Kenvue during the 3rd quarter worth $28,000. Venturi Wealth Management LLC acquired a new position in shares of Kenvue during the 3rd quarter worth $28,000. Finally, Cullen Frost Bankers Inc. acquired a new position in shares of Kenvue during the 3rd quarter worth $29,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KVUE. William Blair began coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein began coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. Royal Bank of Canada lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Finally, The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $24.85.

Kenvue Stock Performance

NYSE KVUE traded up $0.08 during midday trading on Friday, hitting $19.20. The company had a trading volume of 15,941,057 shares, compared to its average volume of 15,351,688. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The firm has a fifty day simple moving average of $19.82 and a two-hundred day simple moving average of $20.12. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s revenue was down 2.7% compared to the same quarter last year. On average, research analysts predict that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.